CD33 and acute lymphoblastic leukemia: One autologous therapy (NCT05662904) treats acute lymphoblastic leukemia (ALL) by inactivating the CD33 gene in the patient’s HSPCs to make them immune to the CD33-specific antibody-drug conjugate Gemtuzumab-ozogamicin (GO), allowing escalation of GO doses (Godwin et al., 2017).